Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAXGet Rating) saw a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 32,100 shares, a drop of 9.8% from the December 15th total of 35,600 shares. Based on an average daily trading volume, of 199,900 shares, the days-to-cover ratio is presently 0.2 days.

Evaxion Biotech A/S Price Performance

EVAX traded down $0.02 on Tuesday, hitting $1.61. 84,850 shares of the company’s stock were exchanged, compared to its average volume of 991,517. Evaxion Biotech A/S has a fifty-two week low of $1.41 and a fifty-two week high of $3.64. The company has a current ratio of 6.47, a quick ratio of 6.47 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $1.90 and a 200-day moving average price of $2.34. The stock has a market cap of $38.42 million, a price-to-earnings ratio of -1.50 and a beta of 0.75.

Evaxion Biotech A/S (NASDAQ:EVAXGet Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.10. As a group, equities analysts anticipate that Evaxion Biotech A/S will post -0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer dropped their price target on shares of Evaxion Biotech A/S from $16.00 to $11.00 and set an “outperform” rating on the stock in a research note on Thursday, November 17th.

About Evaxion Biotech A/S

(Get Rating)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

See Also

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.